261 related articles for article (PubMed ID: 35090043)
1. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
[TBL] [Abstract][Full Text] [Related]
2. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
3. Modern developments in germline pharmacogenomics for oncology prescribing.
Reizine NM; O'Donnell PH
CA Cancer J Clin; 2022 Jul; 72(4):315-332. PubMed ID: 35302652
[TBL] [Abstract][Full Text] [Related]
4. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
[TBL] [Abstract][Full Text] [Related]
5. Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes.
Hutchcraft ML; Lin N; Zhang S; Sears C; Zacholski K; Belcher EA; Durbin EB; Villano JL; Cavnar MJ; Arnold SM; Ueland FR; Kolesar JM
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572750
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
7. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
8. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of population-level pharmacogenetic actionability in Alabama.
Davis BH; Williams K; Absher D; Korf B; Limdi NA
Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
[TBL] [Abstract][Full Text] [Related]
10. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
[TBL] [Abstract][Full Text] [Related]
11. The Role of Pharmacogenomics in Opioid Prescribing.
Wong AK; Somogyi AA; Rubio J; Philip J
Curr Treat Options Oncol; 2022 Oct; 23(10):1353-1369. PubMed ID: 36001223
[TBL] [Abstract][Full Text] [Related]
12. Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka.
Ranasinghe P; Sirisena N; Vishnukanthan T; Ariadurai JN; Thilakarathne S; Priyadarshani CDN; Bhagya Hendalage DP; Dissanayake VHW
BMC Med Genomics; 2024 May; 17(1):143. PubMed ID: 38789983
[TBL] [Abstract][Full Text] [Related]
13. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis.
Reid P; Danahey K; Lopez Velazquez M; Ratain MJ; O'Donnell PH
Clin Exp Rheumatol; 2021; 39(6):1385-1393. PubMed ID: 33506753
[TBL] [Abstract][Full Text] [Related]
14. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
O'Donnell PH; Ratain MJ
Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic potential in advanced cancer patients.
Nichols D; Arnold S; Weiss HL; Wu J; Durbin EB; Miller R; Kolesar J
Am J Health Syst Pharm; 2019 Mar; 76(7):415-423. PubMed ID: 31361818
[TBL] [Abstract][Full Text] [Related]
16. Potentially actionable pharmacogenetic variants and symptom control medications in oncology.
Patel JN; Boselli D; Jandrisevits EJ; Hamadeh IS; Salem A; Meadors P; Walsh D
Support Care Cancer; 2021 Oct; 29(10):5927-5934. PubMed ID: 33758969
[TBL] [Abstract][Full Text] [Related]
17. Implementing comprehensive pharmacogenomics in a community hospital-associated primary care setting.
Wick JA; Schmidlen T; Grande K; Moretz C; Ashcraft K; Green J; Moyer N; Blaxall BC
J Am Pharm Assoc (2003); 2023; 63(1):188-192. PubMed ID: 36243653
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing.
Kimpton JE; Carey IM; Threapleton CJD; Robinson A; Harris T; Cook DG; DeWilde S; Baker EH
Br J Clin Pharmacol; 2019 Dec; 85(12):2734-2746. PubMed ID: 31454087
[TBL] [Abstract][Full Text] [Related]
19. Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.
Haidar CE; Crews KR; Hoffman JM; Relling MV; Caudle KE
Annu Rev Genomics Hum Genet; 2022 Aug; 23():449-473. PubMed ID: 35537468
[TBL] [Abstract][Full Text] [Related]
20. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
Lee YM; Danahey K; Knoebel RW; Ratain MJ; Meltzer DO; O'Donnell PH
Pharmacogenet Genomics; 2019 Feb; 29(2):23-30. PubMed ID: 30531378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
